Ultragenyx Pharmaceutical Inc. (RARE) financial statements (2022 and earlier)

Company profile

Business Address 60 LEVERONI COURT
NOVATO, CA 94949
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7407378469651,202766813
Cash and cash equivalents308198291384714197336
Short-term investments433540555582488568478
Restricted cash and investments 1010111111
Receivables28252525232815
Inventory, net of allowances, customer advances and progress billings16151512131411
Inventory16151512131411
Other undisclosed current assets72595457476366
Total current assets:8578479491,0711,295872906
Noncurrent Assets
Operating lease, right-of-use asset35373939413837
Property, plant and equipment14111910588744948
Long-term investments and receivables2592041288211 4
Long-term investments2592041288211 4
Intangible assets, net (including goodwill)175175175175176176176
Goodwill44444444444444
Intangible assets, net (excluding goodwill)131131131131131131131
Restricted cash and investments2222222
Other noncurrent assets2116139953
Other undisclosed noncurrent assets3384102133153127138
Total noncurrent assets:666638563527464396408
TOTAL ASSETS:1,5221,4851,5121,5981,7601,2681,314
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities163125113981219181
Accounts payable1716221613119
Accrued liabilities14611091831088072
Deferred revenue9 42567103135
Debt1   0  
Other undisclosed current liabilities911104184
Total current liabilities:181136127127190201220
Noncurrent Liabilities
Long-term debt and lease obligation31   393736
Finance lease, liability0   1  
Operating lease, liability30   393736
Liabilities, other than long-term debt34343333333333
Deferred income tax liabilities33333333333333
Other liabilities10     
Other undisclosed noncurrent liabilities353381380383343331329
Total noncurrent liabilities:418415413416416401399
Total liabilities:600551540543605602618
Stockholders' equity
Stockholders' equity attributable to parent9239349721,0551,154666696
Common stock0000000
Additional paid in capital2,9972,8852,8502,8102,7732,2612,221
Accumulated other comprehensive income (loss)(1)000111
Accumulated deficit(2,074)(1,951)(1,878)(1,756)(1,620)(1,596)(1,527)
Total stockholders' equity:9239349721,0551,154666696
TOTAL LIABILITIES AND EQUITY:1,5221,4851,5121,5981,7601,2681,314

Income statement (P&L) ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Revenues83828799928162
Gross profit:83828799928162
Operating expenses(182)(167)(170)(206)(188)(132)(125)
Other undisclosed operating loss(4)(4)     
Operating loss:(103)(90)(83)(107)(96)(50)(63)
Nonoperating income (expense)0(0)0(0)122
Investment income, nonoperating0001112
Other nonoperating income (expense)(0)(0)(0)(1)010
Other undisclosed loss from continuing operations before equity method investments, income taxes(0)   (0)  
Loss from continuing operations before equity method investments, income taxes:(103)(90)(82)(107)(95)(48)(61)
Other undisclosed income (loss) from continuing operations before income taxes(20)17(40)(29)71(20)87
Income (loss) from continuing operations before income taxes:(122)(73)(122)(136)(24)(69)26
Income tax expense(0)(0)(0)(0)(0)(0)(0)
Net income (loss) available to common stockholders, diluted:(122)(73)(122)(136)(24)(69)25

Comprehensive Income ($ in millions)

12/31/2021
Q4
9/30/2021
Q3
6/30/2021
Q2
3/31/2021
Q1
12/31/2020
Q4
9/30/2020
Q3
6/30/2020
Q2
Net income (loss):(122)(73)(122)(136)(24)(69)25
Other comprehensive income (loss)(1)(0)0(1)(0)(0)3
Comprehensive income (loss), net of tax, attributable to parent:(124)(73)(122)(137)(24)(69)28

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: